These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 7508533)
1. AML: immunophenotypic heterogeneity and prognostic significance of c-kit expression. Reuss-Borst MA; Bühring HJ; Schmidt H; Müller CA Leukemia; 1994 Feb; 8(2):258-63. PubMed ID: 7508533 [TBL] [Abstract][Full Text] [Related]
2. The product of the proto-oncogene c-kit (P145c-kit) is a human bone marrow surface antigen of hemopoietic precursor cells which is expressed on a subset of acute non-lymphoblastic leukemic cells. Bühring HJ; Ullrich A; Schaudt K; Müller CA; Busch FW Leukemia; 1991 Oct; 5(10):854-60. PubMed ID: 1720490 [TBL] [Abstract][Full Text] [Related]
3. CD117 (c-kit) is a restricted antigen of acute myeloid leukemia and characterizes early differentiative levels of M5 FAB subtype. Cascavilla N; Musto P; D'Arena G; Melillo L; Carella AM; Petrilli MP; Sanpaolo G; Carotenuto M Haematologica; 1998 May; 83(5):392-7. PubMed ID: 9658721 [TBL] [Abstract][Full Text] [Related]
4. Changes in phenotype and proliferative potential of human acute myeloblastic leukemia cells in culture with stem cell factor. Ikeda H; Kanakura Y; Furitsu T; Kitayama H; Sugahara H; Nishiura T; Karasuno T; Tomiyama Y; Yamatodani A; Kanayama Y Exp Hematol; 1993 Dec; 21(13):1686-94. PubMed ID: 7694869 [TBL] [Abstract][Full Text] [Related]
5. Expression of the c-kit proto-oncogene in myeloproliferative disorders and myelodysplastic syndromes. Siitonen T; Savolainen ER; Koistinen P Leukemia; 1994 Apr; 8(4):631-7. PubMed ID: 7512174 [TBL] [Abstract][Full Text] [Related]
6. Epitope mapping and functional studies with three monoclonal antibodies to the c-kit receptor tyrosine kinase, YB5.B8, 17F11, and SR-1. Ashman LK; Bühring HJ; Aylett GW; Broudy VC; Müller C J Cell Physiol; 1994 Mar; 158(3):545-54. PubMed ID: 7510297 [TBL] [Abstract][Full Text] [Related]
7. The c-kit molecule and the surface immunophenotype of human acute leukemia. Kubota A; Okamura S; Shimoda K; Harada M; Niho Y Leuk Lymphoma; 1994 Aug; 14(5-6):421-8. PubMed ID: 7529077 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of erythroid differentiation by stem cell factor in K562 cells expressing the c-kit gene. Ogawa K; Tashima M; Toi T; Sawai H; Sawada H; Fujita J; Maruyama Y; Okuma M Exp Hematol; 1994 Jan; 22(1):45-51. PubMed ID: 7506674 [TBL] [Abstract][Full Text] [Related]
9. Mast cell growth factor, a ligand for the receptor encoded by c-kit, affects the growth in culture of the blast cells of acute myeloblastic leukemia. Wang C; Koistinen P; Yang GS; Williams DE; Lyman SD; Minden MD; McCulloch EA Leukemia; 1991 Jun; 5(6):493-9. PubMed ID: 1711640 [TBL] [Abstract][Full Text] [Related]
10. Expression of the YB5.B8 antigen (c-kit proto-oncogene product) in normal human bone marrow. Ashman LK; Cambareri AC; To LB; Levinsky RJ; Juttner CA Blood; 1991 Jul; 78(1):30-7. PubMed ID: 1712644 [TBL] [Abstract][Full Text] [Related]
11. CD117/CD34 expression in leukemic blasts. Wells SJ; Bray RA; Stempora LL; Farhi DC Am J Clin Pathol; 1996 Aug; 106(2):192-5. PubMed ID: 8712172 [TBL] [Abstract][Full Text] [Related]
12. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Drexler HG Leukemia; 1996 Apr; 10(4):588-99. PubMed ID: 8618433 [TBL] [Abstract][Full Text] [Related]
13. Expression of c-kit receptor (CD117) and CD34 in leukemic cells. Muroi K; Nakamura M; Amemiya Y; Suda T; Miura Y Leuk Lymphoma; 1995 Jan; 16(3-4):297-305. PubMed ID: 7536510 [TBL] [Abstract][Full Text] [Related]
14. The c-kit proto-oncogene receptor is expressed on a subset of human CD3-CD4-CD8- (triple-negative) thymocytes. deCastro CM; Denning SM; Langdon S; Vandenbark GR; Kurtzberg J; Scearce R; Haynes BF; Kaufman RE Exp Hematol; 1994 Sep; 22(10):1025-33. PubMed ID: 7522182 [TBL] [Abstract][Full Text] [Related]
15. Expression of type III receptor tyrosine kinases FLT3 and KIT and responses to their ligands by acute myeloid leukemia blasts. Stacchini A; Fubini L; Severino A; Sanavio F; Aglietta M; Piacibello W Leukemia; 1996 Oct; 10(10):1584-91. PubMed ID: 8847893 [TBL] [Abstract][Full Text] [Related]
16. [Correlation of immunophenotype to cytogenetics and clinical features of adult acute myeloid leukemia]. Wang XB; Zheng JE; Gu JX; Yao JX; Yang J; Liu J; Li XQ; He YL; Yu JM; Wei J; Liu ZP; Huang SA Ai Zheng; 2005 Jun; 24(6):667-71. PubMed ID: 15946475 [TBL] [Abstract][Full Text] [Related]
18. Prognostic value of cell marker analysis in de novo acute myeloid leukemia. Del Poeta G; Stasi R; Venditti A; Suppo G; Aronica G; Bruno A; Masi M; Tabilio A; Papa G Leukemia; 1994 Mar; 8(3):388-94. PubMed ID: 7907393 [TBL] [Abstract][Full Text] [Related]
19. Flow cytometric analysis of cell-surface and intracellular antigens in leukemia diagnosis. Knapp W; Strobl H; Majdic O Cytometry; 1994 Dec; 18(4):187-98. PubMed ID: 7534675 [TBL] [Abstract][Full Text] [Related]
20. High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis. Graf M; Reif S; Hecht K; Pelka-Fleischer R; Pfister K; Schmetzer H Am J Hematol; 2005 May; 79(1):26-35. PubMed ID: 15849776 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]